CALC
CalciMedica, Inc.Healthcare·Biotechnology
--
$0M market cap
Revenue
$0.0M
Free Cash Flow
$-9.7M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancre
2-Year Price History
$0.63-87.7%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -5.6 | -5.6 | 5.0 | -4.9 | -4.9 | -0.0 | 8.2 | 0.0 | 15.0 | -405.4% | -17.6x | -- |
| Act | 2025-Q4 | 0.0 | -10.4 | -4.4 | -10.8 | -4.9 | -4.9 | -0.0 | 13.0 | 9.7 | 15,011 | -180.8% | -32.1x | -- |
Valuation & Metrics
Market Stats
Price--
Market Cap$0M
Enterprise Value$-8M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield0.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-5.8M
Free Cash Flow$-9.7M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-293.1%
WC Change % Rev0.0%
Interest Coverage-24.9x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.2M
Days to Cover1.1
Change (vs Prior)-54.9%
Need at least 2 settlement dates for chart
Employees
Headcount14
Revenue / Employee$0
Gross Profit / Employee$-500
Cash Runway
10.1months
CRITICAL
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
2.7%(-62.9% YoY)
18 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
2.0%(-6.6% YoY)
5 filers
Vanguard, iShares, SPDR
Market makers
1.2%(+1.2% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| JANE STREET GROUP, LLCMM | $96K | $1.19 | +$86K | +$96K | -0.1% | $92.10B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $91K | $0.54 | +$91K | +$91K | — | $4.04T |
| RENAISSANCE TECHNOLOGIES LLC | $69K | $2.95 | +$21K | +$50K | +1.2% | $63.91B |
| 180 WEALTH ADVISORS, LLC | $68K | $0.94 | +$51K | +$59K | -0.4% | $876M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $67K | $3.13 | +$13K | +$15K | +2.3% | $1.61T |
| Cambridge Investment Research Advisors, Inc. | $32K | $1.08 | +$20K | +$19K | -0.4% | $38.49B |
| Stonehage Fleming Financial Services Holdings Ltd | $29K | $3.08 | +$0 | +$29K | -0.5% | $2.75B |
| VANGUARD FIDUCIARY TRUST COPassive | $25K | $0.54 | +$25K | +$25K | — | $395.83B |
| HRT FINANCIAL LP | $21K | $0.54 | +$21K | +$21K | -0.6% | $39.46B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $17K | $0.54 | +$17K | +$17K | -0.6% | $77.14B |
| GSA CAPITAL PARTNERS LLP | $13K | $0.54 | +$13K | +$13K | -5.9% | $1.61B |
| Virtu Financial LLCMM | $10K | $0.54 | +$10K | +$10K | -2.0% | $2.41B |
| STATE STREET CORPPassive | $9K | $0.54 | +$9K | +$9K | -0.2% | $2.89T |
| TritonPoint Partners, LLC | $8K | $6.59 | +$0 | +$8K | +0.6% | $272M |
| FIRST MANHATTAN CO | $7K | $4.01 | +$0 | +$0 | -0.2% | $36.06B |
| SIMPLEX TRADING, LLC | $7K | $0.54 | +$7K | +$7K | +2.5% | $3.23B |
| NORTHERN TRUST CORPPassive | $7K | $6.59 | +$0 | +$7K | -0.2% | $755.34B |
| Ground Swell Capital, LLC | $7K | $0.54 | +$7K | +$7K | +1.4% | $50.7M |
| Sound View Wealth Advisors Group, LLC | $5K | $1.60 | −$5K | +$5K | +0.0% | $1.47B |
| Rockefeller Capital Management L.P. | $3K | $3.08 | −$3K | +$3K | -0.1% | $56.28B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.10%
avg per quarter
Holders (ex-self)
-0.10%
excl. this stock
Buyers (this Q)
-1.31%
9 buyers · $0.00B in
Sellers (this Q)
-0.01%
5 sellers · $0.00B out
alpha coverage: 80% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+4.3%
how holders react when this stock falls
On quiet Qs
+27.8%
−10% to +10% baseline
On rallies (+10%+)
+0.5%
how they react when this stock rises
Holders' portfolio flow this Q
+6.5%
inflows — adds are organic
Sellers' portfolio flow this Q
+2.6%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-6.6%
Holder mid (any stock)
-7.6%
Holder rally (any stock)
-6.5%
Biggest decreases this quarter
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)exited−$8.6MSoleus Capital Management, L.P.exited−$4.5MAisling Capital Management LPexited−$3.4MBOOTHBAY FUND MANAGEMENT, LLCexited−$506KENVESTNET ASSET MANAGEMENT INCexited−$416KSummit Financial, LLCexited−$234KATRIA INVESTMENTS LLCexited−$190KCetera Investment Advisersexited−$147KJ. Goldman & Co LPexited−$125KMILLENNIUM MANAGEMENT LLCexited−$98K
New buyers this quarter
VANGUARD CAPITAL MANAGEMENT LLC+$0.00BVANGUARD FIDUCIARY TRUST CO+$0.00BHRT FINANCIAL LP+$0.00Bα-0.6SUSQUEHANNA INTERNATIONAL GROUP, LLP+$0.00Bα-0.6GSA CAPITAL PARTNERS LLP+$0.00Bα-5.9Virtu Financial LLC+$0.00Bα-2.0STATE STREET CORP+$0.00Bα-0.2SIMPLEX TRADING, LLC+$0.00Bα+2.5Ground Swell Capital, LLC+$0.00Bα+1.4
Top-5 holders · 66.1%
JANE STREET GROUP, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
RENAISSANCE TECHNOLOGIES LLC--
180 WEALTH ADVISORS, LLC--
GEODE CAPITAL MANAGEMENT, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)—Soleus Capital Management, L.P.—Aisling Capital Management LP—Stonepine Capital Management, LLC—Alyeska Investment Group, L.P.—ORBIMED ADVISORS LLC—BML Capital Management, LLC—RENAISSANCE TECHNOLOGIES LLC128KBOOTHBAY FUND MANAGEMENT, LLC—Hudson Bay Capital Management LP—
Analyst Coverage
Analyst Coverage
Analyst Ratings
2
1
Buy: 2Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$67K
8 txns · 4 insiders · 25,039 sh
Sells ($, 12mo)
$4K
1 txn · 1 insider · 1,000 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$184K
21 txns · 2 insiders · 74,427 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-09-18 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 2,500 | $3.07 | $8K | $258K |
| 2025-09-15 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 3,400 | $2.68 | $9K | $219K |
| 2025-09-12 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 5,000 | $3.12 | $16K | $244K |
| 2025-09-09 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 2,343 | $3.15 | $7K | $231K |
| 2025-08-29 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 800 | $2.74 | $2K | $194K |
| 2025-08-28 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 9,200 | $2.86 | $26K | $201K |
| 2025-08-21 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 3,508 | $2.79 | $10K | $170K |
| 2025-08-20 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 2,000 | $2.72 | $5K | $156K |
| 2025-08-19 | BUY | Hebbar Sudarshan | officer: Chief Medical Officer | 9,563 | $2.82 | $27K | $174K |
| 2025-08-19 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 1,000 | $2.79 | $3K | $155K |
| 2025-08-15 | BUY | Hebbar Sudarshan | officer: Chief Medical Officer | 4,392 | $2.79 | $12K | $145K |
| 2025-08-15 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 5,076 | $2.90 | $15K | $158K |
| 2025-08-14 | BUY | Hebbar Sudarshan | officer: Chief Medical Officer | 1,584 | $2.58 | $4K | $123K |
| 2025-07-28 | BUY | Stauderman Kenneth A. | officer: Chief Scientific Officer | 1,000 | $3.96 | $4K | $51K |
| 2025-07-25 | SELL | Stauderman Kenneth A. | officer: Chief Scientific Officer | 1,000 | $3.65 | $4K | $0 |
| 2025-07-22 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 1,500 | $3.77 | $6K | $186K |
| 2025-07-21 | BUY | Leheny A. Rachel | director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER | 1,000 | $3.40 | $3K | $12K |
| 2025-07-21 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 1,500 | $3.37 | $5K | $161K |
| 2025-07-18 | BUY | Roberts Eric W | director, 10 percent owner, officer: CHIEF BUSINESS OFFICER | 2,000 | $2.88 | $6K | $133K |
| 2025-07-18 | BUY | WILSON ROBERT N | director | 4,500 | $2.87 | $13K | $1.21M |
Order Flow (FINRA, ~3w lag)
42.2%retail-5.4pp
5.8%dark-0.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
CalciMedica, Inc.: A Distressed Clinical-Stage Burn-Box Navigating Negative Equity and Pipeline Failure
Overall Risk
9/10
Fraud
4/10
Dilution
9/10
Insolvency
10/10
Earnings Overstated
3/10
Hidden Liabilities
7/10
Legal
4/10
Audit Warnings
10/10
Hidden Upside
2/10
Contextually Acceptable
3/10